MedAdvisor (ASX:MDR) said that the proposed acquisition of 100% of MedAdvisor International and its subsidiaries and all intellectual property carries a headline price of AU$35 million, according to a Friday Australian bourse filing.
MedAdvisor International conducts the firm's Australia and New Zealand business.
An uncapped contingent consideration comprised of a three-year earn-out based on performance will also be available.
It granted the acquirer an exclusive right to conduct due diligence on the business and negotiate formal sale documentation in line with the letter of intent for around five weeks, with the ability to extend for a further two weeks.
Assuming due diligence and negotiations proceed positively, the timeframe for the execution of a binding sale agreement is expected to be around June 30.
Its shares plummeted 28% in recent trading on Friday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。